UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 109.

Greuter, T; Biedermann, L; Rogler, G; Sauter, B; Seibold, F (2016). Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology journal, 4(1):97-104.

Safroneeva, E; Vavricka, S R; Fournier, N; Pittet, V; Peyrin-Biroulet, L; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Alimentary Pharmacology & Therapeutics, 42(8):977-989.

Safroneeva, E; Vavricka, S; Fournier, N; Seibold, F; Mottet, C; Nydegger, A; Ezri, J; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary Pharmacology & Therapeutics, 42(5):540-548.

Casén, C; Vebø, H C; Sekelja, M; Hegge, F T; Karlsson, M K; Ciemniejewska, E; Dzankovic, S; Frøyland, C; Nestestog, R; Engstrand, L; Munkholm, P; Nielsen, O H; Rogler, G; Simrén, M; Öhman, L; Vatn, M H; Rudi, K (2015). Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology & Therapeutics, 42(1):71-83.

Schreiber, S; Dignass, A U; Hartmann, H; Kruis, W; Rogler, G; Siegmund, B; Stallmach, A; Witte, C; Bokemeyer, B (2015). Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung. Zeitschrift für Gastroenterologie, 53(6):591-602.

Lutz, C; Mozaffari, M; Tosevski, V; Caj, M; Cippà, P; McRae, B L; Graff, C L; Rogler, G; Fried, M; Hausmann, M (2015). Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. Clinical and Experimental Immunology, 181(2):343-356.

Rogler, G (2015). Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Alimentary Pharmacology & Therapeutics, 41(8):785-786.

van Assche, G; Dignass, A; Bokemeyer, B; Danese, S; Gionchetti, P; Moser, G; Beaugerie, L; Gomollón, F; Häuser, W; Herrlinger, K; Oldenburg, B; Panes, J; Portela, F; Rogler, G; Stein, J; Tilg, H; Travis, S; Lindsay, J O (2015). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Revista de gastroenterología de México, 80(1):74-106.

Rogler, G; Biedermann, L (2015). Clinical utility of biomarkers in IBD. Current Gastroenterology Reports, 17(7):17:26.

Biedermann, L; Fournier, N; Misselwitz, B; Frei, P; Zeitz, J; Manser, C N; Pittet, V; Juillerat, P; von Känel, R; Fried, M; Vavricka, S R; Rogler, G (2015). High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation-data from the swiss IBD cohort study. Journal of Crohn's & colitis, 9(10):819-829.

Rogler, G; Vavricka, S R; Biedermann, L (2015). Integrating imaging into clinical practice in inflammatory bowel disease. Digestive Diseases, 33 Suppl:37-43.

Spalinger, M R; Kasper, S; Chassard, C; Raselli, T; Frey-Wagner, I; Gottier, C; Lang, S; Atrott, K; Vavricka, S R; Mair, F; Becher, B; Lacroix, C; Fried, M; Rogler, G; Scharl, M (2015). PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal immunology, 8(4):918-929.

Barthel, C; Wiegand, S; Scharl, S; Scharl, M; Frei, P; Vavricka, S R; Fried, M; Sulz, M C; Wiegand, N; Rogler, G; Biedermann, L (2015). Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Open Nutrition Journal, 14:78.

Greuter, T; Lang, S; Holler, E; Hawkey, C J; Rogler, G; Biedermann, L (2015). Serum REG3alpha and C-reactive protein levels in Crohn's disease patients undergoing immunoablation and autologous hemopoetic stem cell transplantation in the ASTIC trial. Digestion, 92(2):83-89.

Pineton de Chambrun, G; Body-Malapel, M; Frey-Wagner, I; Djouina, M; Deknuydt, F; Atrott, K; Esquerre, N; Altare, F; Neut, C; Arrieta, M C; Kanneganti, T-D; Rogler, G; Colombel, J-F; Cortot, A; Desreumaux, P; Vignal, C (2014). Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal immunology, 7(3):589-601.

Seibold, F; Fournier, N; Beglinger, C; Mottet, C; Pittet, V; Rogler, G (2014). Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's & colitis, 8(1):56-63.

Jirkof, P; Leucht, K; Cesarovic, N; Caj, M; Nicholls, F; Rogler, G; Arras, M; Hausmann, M (2013). Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice. Laboratory Animals, 47(4):274-283.

Bickelhaupt, S; Pazahr, S; Chuck, N; Blume, I; Froehlich, J M; Cattin, R; Raible, S; Bouquet, H; Bill, U; Rogler, G; Frei, P; Boss, A; Patak, M A (2013). Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. Neurogastroenterology and Motility, 25(6):467-473.

Biedermann, L; Kerl, K; Rogler, G; Hofbauer, G F L (2013). Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. Inflammatory Bowel Diseases, 19(1):E4-6.

Rogler, G (2013). Evidenzbasierte und stadienadaptierte Therapie chronisch-entzündlicher Darmerkrankungen: Pro Step-up. Deutsche Medizinische Wochenschrift, 138(36):1778.

Bauerfeind, P; Schöfl, R; Müllhaupt, B; Schwizer, W; Wirth, H-P; Rogler, G; Fried, M; Quigley, E; Tytgat, G N J (2013). Gastro-Highlights 2012. Praxis, 102(4):197-210.

Bentz, S; Cee, A; Endlicher, E; Wojtal, K A; Naami, A; Pesch, T; Lang, S; Schubert, P; Fried, M; Weber, A; Coy, J F; Goelder, S; Knüchel, R; Hausmann, M; Rogler, G (2013). Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion, 88(3):182-192.

Panes, J; Bouhnik, Y; Reinisch, W; Stoker, J; Taylor, S A; Baumgart, D C; Danese, S; Halligan, S; Marincek, B; Matos, C; Peyrin-Biroulet, L; Rimola, J; Rogler, G; van Assche, G; Ardizzone, S; Ba-Ssalamah, A; Bali, M A; Bellini, D; Biancone, L; Castiglione, F; Ehehalt, R; Grassi, R; Kucharzik, T; Maccioni, F; Maconi, G; Magro, F; Martín-Comín, J; Morana, G; Pendsé, D; Sebastian, S; Signore, A; Tolan, D; Tielbeek, J A; Weishaupt, D; Wiarda, B; Laghi, A (2013). Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's & colitis, 7(7):556-585.

Leucht, K; Caj, M; Fried, M; Rogler, G; Hausmann, M (2013). Impaired removal of Vβ8(+) lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim). Clinical and Experimental Immunology, 173(3):493-501.

Xue, B; Müller, M H; Li, J; Pesch, T; Kasparek, M S; Sibaev, A; Hausmann, M; Rogler, G; Kreis, M E (2013). Mast cells and the cyclooxygenase pathway mediate colonic afferent nerve sensitization in a murine colitis model. Autonomic Neuroscience, 174(1-2):47-53.

Scharl, M; Mwinyi, J; Fischbeck, A; Leucht, K; Eloranta, J J; Arikkat, J; Pesch, T; Kellermeier, S; Mair, A; Kullak-Ublick, G A; Truninger, K; Noreen, F; Regula, J; Gaj, P; Pittet, V; Mueller, C; Hofmann, C; Fried, M; McCole, D F; Rogler, G (2012). Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 18(5):900-912.

Hetzenecker, A M; Seidl, M C; Kosovac, K; Herfarth, H; Kellermeier, S; Obermeier, F; Falk, W; Schoelmerich, J; Hausmann, M; Rogler, G (2012). Downregulation of the ubiquitin-proteasome system in normal colonic macrophages and reinduction in inflammatory bowel disease. Digestion, 86(1):34-47.

Schwizer, W; Rogler, G; Rösch, T; Bauerfeind, P; Häfner, M; Wirth, H P; Müllhaupt, B; Fried, M (2012). Gastro-Highlights 2011. Zusammenfassung der Referate anlässlich des gastroenterologischen Symposiums am Universitätsspital Zürich vom 10. September 2011 unter der Leitung von Professor Michael Fried. Praxis, 101(1):23-35.

Scharl, M; Wojtal, K A; Becker, H M; Fischbeck, A; Frei, P; Arikkat, J; Pesch, T; Kellermeier, S; Boone, D L; Weber, A; Loessner, M J; Vavricka, S R; Fried, M; McCole, D F; Rogler, G (2012). Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflammatory Bowel Diseases, 18(7):1287-1302.

Vavricka, S R; Bentele, N; Scharl, M; Rogler, G; Zeitz, J; Frei, P; Straumann, A; Binek, J; Schoepfer, A M; Fried, M (2012). Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflammatory Bowel Diseases, 18(8):1523-1530.

Rogler, G; Braegger, C P (2012). Therapie chronisch entzündlicher Darmerkrankungen bei Kindern und Jugendlichen. In: Rogler, G. Aktuelle Therapieoptionen bei chronisch-entzündlichen Darmerkrankungen. Zürich: Uni-Med, 114-119.

Hausmann, M; Leucht, K; Ploner, C; Kiessling, S; Villunger, A; Becker, H; Hofmann, C; Falk, W; Krebs, M; Kellermeier, S; Fried, M; Schölmerich, J; Obermeier, F; Rogler, G (2011). BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. Journal of Biological Chemistry, 286(30):26533-26540.

Vavricka, S R; Spigaglia, S M; Rogler, G; Pittet, V; Michetti, P; Felley, C; Mottet, C; Braegger, C P; Rogler, D; Straumann, A; Bauerfeind, P; Fried, M; Schoepfer, A M (2011). Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 18(3):496-505.

Fischbeck, A; Leucht, K; Frey-Wagner, I; Bentz, S; Pesch, T; Kellermeier, S; Krebs, M; Fried, M; Rogler, G; Hausmann, M; Humpf, H U (2011). Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. Gut, 60(1):55-65.

Scharl, M; Frei, P; Fried, M; Rogler, G; Vavricka, S R (2011). Association between Cogan's syndrome and inflammatory bowel disease: a case series. Journal of Crohn's and Colitis, 5(1):64-68.

Scharl, M; Geisel, S; Vavricka, S R; Rogler, G (2011). Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature. Digestion, 83(1-2):13-17.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Vavricka, S R; Brun, L; Ballabeni, P; Pittet, V; Prinz Vavricka, B M; Zeitz, J; Rogler, G; Schoepfer, A M (2011). Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. American Journal of Gastroenterology, 106(1):110-119.

Rogler, G (2011). Is this stricture inflammatory? Digestion, 83(4):261-262.

Scharl, M; Leucht, K; Frey-Wagner, I; Zeitz, J; Hausmann, M; Fischbeck, A; Liebisch, G; Kellermeier, S; Pesch, T; Arikkat, J; Schmitz, G; Fried, M; Yildiz, Y; Rogler, G (2011). Knock-out of β-glucosidase 2 has no influence on dextran sulfate sodium-induced colitis. Digestion, 84(2):156-167.

Bentz, S; Pesch, T; Wolfram, L; de Vallière, C; Leucht, K; Fried, M; Coy, J F; Hausmann, M; Rogler, G (2011). Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology, 300(4):G598-G607.

Frei, P; Weber, A; Geier, A; Mertens, J C; Kohler, S; Rogler, G; Mullhaupt, B (2011). Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetil-associated colitis. Transplant Infectious Disease, 13(4):416-418.

Frei, P; Biedermann, L; Rogler, G (2011). Morbus Crohn und Colitis ulcerosa – Wichtiges für den Nicht-Gastroenterologen. Swiss Medical Forum, 11(41):718-726.

Rogler, G (2011). Pathogenesis of strictures in ulcerative colitis: A field to explore. Digestion, 84(1):10-11.

Scharl, M; Weber, A; Fürst, Alois; Farkas, S; Jehle, E; Pesch, T; Kellermeier, S; Fried, M; Rogler, G (2011). Potential role for snail family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflammatory Bowel Diseases, 17(9):1907-1916.

Scharl, M; McCole, D F; Weber, A; Vavricka, S R; Frei, P; Kellermeier, S; Pesch, T; Fried, M; Rogler, G (2011). Protein tyrosine phosphatase N2 regulates TNFα-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut, 60(2):189-197.

Meier, J K H; Scharl, M; Miller, S N; Brenmoehl, J; Hausmann, M; Kellermeier, S; Schölmerich, J; Rogler, G (2011). Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures. Inflammatory Bowel Diseases, 17(1):202-212.

Nielsen, O H; Seidelin, J B; Munck, L K; Rogler, G (2011). Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine, 270(1):15-28.

Rieder, F; Schleder, S; Wolf, A; Dirmeier, A; Strauch, U; Obermeier, F; Lopez, R; Spector, L; Fire, E; Yarden, J; Rogler, G; Dotan, N; Klebl, F (2010). Serum anti-glycan antibodies predict complicated Crohn's disease behavior: A cohort study. Inflammatory Bowel Diseases, 16(8):1367-1375.

Schoepfer, A M; Vavricka, S R; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Seibold, F; Straumann, A; Michetti, P (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory Bowel Diseases, 16(6):933-938.

Weigert, J; Obermeier, F; Neumeier, M; Wanninger, J; Filarsky, M; Bauer, S; Aslanidis, C; Rogler, G; Ott, C; Schäffler, A; Schölmerich, J; Buechler, C (2010). Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflammatory Bowel Diseases, 16(4):630-637.

Ratzinger, S; Eble, J A; Pasoldt, A; Opolka, A; Rogler, G; Grifka, J; Grässel, S (2010). Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal trac. Matrix Biology, 29(3):177-193.

Landfried, K; Bataille, F; Rogler, G; Brenmoehl, J; Kosovac, K; Wolff, D; Hilgendorf, I; Hahn, J; Edinger, M; Hoffmann, P; Obermeier, F; Schoelmerich, J; Andreesen, R; Holler, E (2010). Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clinical and Experimental Immunology, 159(1):87-92.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Kosovac, K; Brenmoehl, J; Holler, E; Falk, W; Schoelmerich, J; Hausmann, M; Rogler, G (2010). Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflammatory Bowel Diseases, 16(8):1311-1321.

Scharl, M; Rogler, G (2010). Biologicals in der Gastroenterologie am Beispiel der Anti-TNF-Antikörper. Deutsche Medizinische Wochenschrift, 135(45):2243-2252.

Nichita, C; Stelle, M; Vavricka, S; El-Wafa Ali, A; Ballabeni, P; de Saussure, P; Straumann, A; Rogler, G; Michetti, P (2010). Clinical experience with Adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion, 81(2):78-85.

Bentz, S; Hausmann, M; Piberger, H; Kellermeier, S; Paul, S; Held, L; Falk, W; Obermeier, F; Fried, M; Schölmerich, J; Rogler, G (2010). Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. Digestion, 81(4):252-264.

Xu, L; Hausmann, M; Dietmaier, W; Kellermeier, S; Pesch, T; Stieber-Gunckel, M; Lippert, E; Klebl, F; Rogler, G (2010). Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer, 10:302.

Vavricka, S R; Rogler, G (2010). Fistula treatment: The unresolved challenge. Digestive Diseases, 28(3):556-564.

Rogler, G (2010). Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Practice & Research: Clinical Gastroenterology, 24(2):157-165.

Juillerat, P; Pittet, V; Vader, J P; Burnand, B; Gonvers, J J; de Saussure, P; Mottet, C; Seibold, F; Rogler, G; Sagmeister, M; Felley, C; Michetti, P; Froehlich, F; et al; Braegger, C P (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European Journal of Gastroenterology & Hepatology, 22(11):1352-1357.

Rogler, G (2010). Is inflammatory bowel disease more severe when it appears at younger ages? Digestion, 81(4):235-346.

Braegger, C P; Rogler, G (2010). Klinische und epidemiologische Aspekte der Zöliakie. Schweizer Zeitschrift für Ernährungsmedizin (SZE), 3:7-10.

Scharl, M; Rogler, G (2010). Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. International Journal of Inflammation, 2010:671258.

Voegtlin, M; Vavricka, S R; Schoepfer, A M; Straumann, A; Voegtlin, J; Rogler, G; Ballabeni, P; Pittet, V; Buser, A; Fried, M; Beglinger, C (2010). Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. Journal of Crohn's and Colitis, 4(6):642-648.

Rieder, F; Georgieva, M; Schirbel, A; Artinger, M; Zügner, A; Blank, M; Brenmoehl, J; Schölmerich, J; Rogler, G (2010). Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflammatory Bowel Diseases, 16(9):1505-1513.

Vavricka, S R; Rogler, G (2010). Recent advances in the etiology and treatment of Crohn's disease. Minerva Gastroenterologica e Dietologica, 56(2):203-211.

Rogler, G (2010). Recognition of commensal microbes: if innate responses are NOD in balance. Expert Review of Clinical Immunology, 6(2):205-210.

Zeitz, J; Huber, M; Rogler, G (2010). Schwerer Verlauf einer Miliartuberkulose bei einem 34-jährigen Patienten mit Colitis ulcerosa und HIV-Infektion unter einer TNF-α-Antikörper-Therapie. Medizinische Klinik, 105(4):314-318.

Rogler, G (2010). The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease. Gut, 59(2):153-154.

Härle, P; Schwarz, S; Langgartner, J; Schölmerich, J; Rogler, G (2010). Volcano-like intermittent bleeding activity for seven years from an arterio-enteric fistula on a kidney graft site after pancreas-kidney transplantation: a case report. Journal of Medical Case Reports, 4:357.

Vavricka, S R; Rogler, G (2009). Treatment of severe ulcerative colitis: differences in elderly patients? Digestive Diseases, 27(3):315-321.

Lang, M; Schlechtweg, M; Kellermeier, S; Brenmoehl, J; Falk, W; Schölmerich, J; Herfarth, H; Rogler, G; Hausmann, M (2009). Gene expression profiles of mucosal fibroblasts from strictured and nonstrictured areas of patients with Crohn's disease. Inflammatory Bowel Diseases, 15(2):212-223.

Vavricka, S; Rogler, G (2009). Therapie des Morbus Crohn. Praxis, 98(2):77-81.

Xue, B; Hausmann, M; Müller, M H; Pesch, T; Karpitschka, M; Kasparek, M S; Hu, W C; Sibaev, A; Rogler, G; Kreis, M E (2009). Afferent nerve sensitivity is decreased by an iNOS-dependent mechanism during indomethacin-induced inflammation in the murine jejunum in vitro. Neurogastroenterology and Motility, 21(3):322-334.

Dreiseitel, A; Schreier, P; Oehme, A; Locher, S; Rogler, G; Piberger, H; Hajak, G; Sand, P G (2009). Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6. Methods and Findings in Experimental and Clinical Pharmacology, 31(1):3-9.

Blaas, S H; Stieber-Gunckel, M; Falk, W; Obermeier, F; Rogler, G (2009). CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clinical and Experimental Immunology, 155(3):534-540.

Nielsen, O H; Rogler, G; Hahnloser, D; Thomsen, O Ø (2009). Diagnosis and management of fistulizing Crohn's disease. Nature Reviews. Gastroenterology & Hepatology, 6(2):92-106.

Liu, C Y; Mueller, M H; Rogler, G; Grundy, D; Kreis, M E (2009). Differential afferent sensitivity to mucosal lipopolysaccharide from Salmonella typhimurium and Escherichia coli in the rat jejunum. Neurogastroenterology and Motility, 21(12):1335-1341+e129.

Rogler, G; Fröhlich, G (2009). Ethische Probleme in der klinischen Praxis der evidenzbasierten Medizin. Praxis, 98(14):757-764.

Herfarth, H H; Grunert, M; Klebl, F; Strauch, U; Feuerbach, S; Schölmerich, J; Rogler, G; Schreyer, A G (2009). Frequency and nature of incidental extra-enteric lesions found on magnetic resonance enterography (MR-E) in patients with inflammatory bowel diseases (IBD). PLoS ONE, 4(4):e4863.

Funke, B; Autschbach, F; Kim, S; Lasitschka, F; Strauch, U; Rogler, G; Gdynia, G; Li, L; Gretz, N; Macher-Goeppinger, S; Sido, B; Schirmacher, P; Meuer, S C; Roth, W (2009). Functional characterisation of decoy receptor 3 in Crohn's disease. Gut, 58(4):483-491.

Zeitz, J; Mullhaupt, B; Fruehauf, H; Rogler, G; Vavricka, S R (2009). Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology, 50(2):653-654.

Rogler, G (2009). Medical management of ulcerative colitis. Digestive Diseases, 27(4):542-549.

Mañé, J; Pedrosa, E; Lorén, V; Ojanguren, I; Fluvià, L; Cabré, E; Rogler, G; Gassull, M A (2009). Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. Journal of Nutrition, 139(3):603-610.

Rogler, G (2009). Preface. Digestive Diseases, 27(3):205.

Hofmann, C; Lippert, E; Falk, W; Schölmerich, J; Rogler, G; Obermeier, F (2009). Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism. Biochemical and Biophysical Research Communications (BBRC), 390(3):908-914.

Scharl, M; Paul, G; Weber, A; Jung, B C; Docherty, M J; Hausmann, M; Rogler, G; Barrett, K E; McCole, D F (2009). Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase n2. Gastroenterology, 137(6):2030-2040.e5.

Gnewuch, C; Liebisch, G; Langmann, T; Dieplinger, B; Mueller, T; Haltmayer, M; Dieplinger, H; Zahn, A; Stremmel, W; Rogler, G; Schmitz, G (2009). Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World Journal of Gastroenterology, 15(25):3134-3141.

Pache, I; Rogler, G; Felley, C (2009). TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Medical Weekly, 139(19-20):278-287.

Vavricka, S R; Rogler, G (2009). Therapie der Colitis ulcerosa. Praxis, 98(4):209-212.

Brenmoehl, J; Miller, S N; Hofmann, C; Vogl, D; Falk, W; Schölmerich, J; Rogler, G (2009). Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World Journal of Gastroenterology, 15(12):1431-1442.

Bataille, F; Rohrmeier, C; Bates, R; Weber, A; Rieder, F; Brenmoehl, J; Strauch, U; Farkas, S; Fürst, Alois; Hofstädter, F; Schölmerich, J; Herfarth, H; Rogler, G (2008). Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflammatory Bowel Diseases, 14(11):1514-1527.

Brenmoehl, J; Falk, W; Göke, M; Schölmerich, J; Rogler, G (2008). Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). International Journal of Colorectal Disease, 23(10):947-955.

Hoffmann, J C; Preiss, J C; Autschbach, F; Buhr, H J; Häuser, W; Herrlinger, K; Höhne, W; Koletzko, S; Krieglstein, C F; Kruis, W; Matthes, H; Moser, G; Reinshagen, M; Rogler, G; Schreiber, S; Schreyer, A G; Sido, B; Siegmund, B; Stallmach, A; Bokemeyer, B; Stange, E F; Zeitz, M (2008). Diagnostik und Therapie des Morbus Crohn: Ergebnisse einer Evidenz-basierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zusammen mit dem Kompetenznetz Chronisch entzündliche Darmerkrankungen. Zeitschrift für Gastroenterologie, 46(9):1094-1146.

Hoffmann, J C; Autschbach, F; Bokemeyer, B; Buhr, H J; Herrlinger, K; Höhne, W; Krieglstein, C; Kruis, W; Moser, G; Preiss, J C; Reinshagen, M; Rogler, G; Schreiber, S; Schreyer, A G; Siegmund, B; Stallmach, A; Stange, E F; Zeitz, M (2008). Kurzfassung der aktualisierten S3-Leitlinie der DGVS und des Kompetenznetzwerkes CED zur Diagnostik und Behandlung des Morbus Crohn. Deutsche Medizinische Wochenschrift, 133(38):1924-1929.

Rogler, G (2008). Nutzen und Risiken der Immunsuppression bei chronisch entzündlichen Darmerkrankungen. Deutsche Medizinische Wochenschrift, 133(38):1917-1921.

Ott, C; Obermeier, F; Thieler, S; Kemptner, D; Bauer, A; Schölmerich, J; Rogler, G; Timmer, A (2008). The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. European Journal of Gastroenterology & Hepatology, 20(9):917-923.

Dreiseitel, A; Schreier, P; Oehme, A; Locher, S; Rogler, G; Piberger, H; Hajak, G; Sand, P G (2008). Inhibition of proteasome activity by anthocyanins and anthocyanidins. Biochemical and Biophysical Research Communications (BBRC), 372(1):57-61.

Hausmann, M; Paul, G; Kellermeier, S; Frey, I; Schölmerich, J; Falk, W; Menzel, K; Fried, M; Herfarth, H; Rogler, G (2008). (GT)n Dinucleotide repeat polymorphism of haem oxygenase-1 promotor region is not associated with inflammatory bowel disease risk or disease course. Clinical and Experimental Immunology, 153(1):81-85.

Hafner, S; Timmer, A; Herfarth, H; Rogler, G; Schölmerich, J; Schäffler, A; Ehrenstein, B; Jilg, W; Ott, C; Strauch, U G; Obermeier, F (2008). The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. European Journal of Gastroenterology & Hepatology, 20(6):561-566.

Hausmann, M; Rogler, G (2008). Immune-non immune networks in intestinal inflammation. Current Drug Targets, 9(5):388-394.

Lippert, E; Gunckel, M; Brenmoehl, J; Bataille, F; Falk, W; Scholmerich, J; Obermeier, F; Rogler, G (2008). Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clinical and Experimental Immunology, 152(2):285-297.

Hausmann, M; Paul, G; Menzel, K; Brunner-Ploss, R; Falk, W; Schölmerich, J; Herfarth, H; Rogler, G (2008). NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Zeitschrift für Gastroenterologie, 46(3):259-265.

Pohl, D; Fox, M; Fried, M; Göke, B; Prinz, C; Mönnikes, H; Rogler, G; Dauer, M; Keller, J; Lippl, F; Schiefke, I; Seidler, U; Allescher, H D; Kandahar Study Group (2008). Do we need gastric acid? Digestion, 77(3-4):184-197.

Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab-Monotherapie versus Kombinationstherapie mit Immunmodulatoren : Aktuelle Therapieempfehlungen einer Schweizer Expertengruppe. Medical Journal (TMJ), (1):32-34.

Hoffmann, J C; Preiss, J C; Autschbach, F; Buhr, H J; Häuser, W; Herrlinger, K; Höhne, W; Koletzko, S; Krieglstein, C F; Kruis, W; Matthes, H; Moser, G; Reinshagen, M; Rogler, G; Schreiber, S; Schreyer, A G; Sido, B; Siegmund, B; Stallmach, A; Bokemeyer, B; Stange, E F; Zeitz, M (2008). S3-Leitlinie "Diagnostik und Therapie des Morbus Crohn". Zeitschrift für Gastroenterologie, 46(9):1094-1146.

Holler, E; Rogler, G; Brenmoehl, J; Hahn, J; Greinix, H; Dickinson, A M; Socie, G; Wolff, D; Finke, J; Fischer, G; Jackson, G; Rocha, V; Hilgendorf, I; Eissner, G; Marienhagen, J; Andreesen, R (2008). The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. International Journal of Immunogenetics, 35(4-5):381-384.

This list was generated on Wed Jul 26 11:37:42 2017 CEST.